Volume Alert - SLXP 138.55 Salix Pharmaceuticals $

Volume Alert - SLXP 138.55 Salix Pharmaceuticals $SLXP Hit a high today of 141.79 Closing the day 11/06/14 at 138.55 -0.95 -0.68% With a day low of 134.40 and a total volume of 6,534,728.

SLXP Recent Posts: http://investorshangout.com/Salix-Pharmaceuti...LXP-55453/

SLXP Salix Pharmaceuticals Recent Headline News

INVESTOR ALERT: Investigation of Salix Pharmaceuticals, Ltd. Announced by Glancy Binkow & Goldberg LLP
Business Wire - Thu Nov 06, 7:42PM CST
Glancy Binkow & Goldberg LLP announces that it is investigating potential claims on behalf of investors of Salix Pharmaceuticals, Ltd. ("Salix" or the "Company" (NASDAQ:SLXP) concerning possible violations of federal securities laws. The investigation is focused on the Company's operations and financial performance and prospects. Salix acquires, develops and commercializes prescription drugs and medical devices in the United States to treat various gastrointestinal diseases.
SLXP: 138.55 (-0.95)

Salix Shares Plummet on Disclosure of Accounting Scandal
at The Street - Thu Nov 06, 6:33PM CST
Salix Pharmaceuticals has been rocked by an accounting scandal involving inventory levels of its key gastrointestinal drugs, forcing the company to cut financial forecasts for the rest of the year.
SLXP: 138.55 (-0.95)

SALIX SHAREHOLDER ALERT: Investor Rights Firm Johnson & Weaver, LLP Announces Investigation of Salix Pharmaceuticals Ltd.
Business Wire - Thu Nov 06, 6:20PM CST
Shareholder Rights Law Firm Johnson & Weaver, LLP is investigating potential violations of state and federal securities laws by Salix Pharmaceuticals Ltd. (NASDAQ: SLXP) and certain of its officers. Salix Pharmaceuticals acquires, develops and commercializes prescription drugs and medical devices to treat various gastrointestinal diseases.
SLXP: 138.55 (-0.95)

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Salix Pharmaceuticals, Ltd. - SLXP
PR Newswire - Thu Nov 06, 5:55PM CST
Pomerantz LLP is investigating claims on behalf of investors of Salix Pharmaceuticals, Ltd. ("Salix Pharmaceuticals" or the "Company" (NASDAQ: SLXP). Such investors are advised to contact Robert S. Willoughby at rswilloughby@pomlaw.com or 888-476-6529, ext. 237.
SLXP: 138.55 (-0.95)

Salix reports 3Q loss, CFO resigns
AP - Thu Nov 06, 4:54PM CST
RALEIGH, N.C. (AP) — Salix Pharmaceuticals Ltd. posted lower-than-expected quarterly results and announced the abrupt resignation of its chief financial officer, and shares of the specialty drugmaker plunged in extended trading Thursday.
SLXP: 138.55 (-0.95)

Indexes Higher; El Pollo Loco Reports In Line
at Investor's Business Daily - Thu Nov 06, 3:56PM CST
The stock market finished moderately higher Thursday with several earnings report emerging after the close. The Nasdaq, S&P 500 and Dow Jones industrial average climbed 0.4%. Volume was lighter on both main exchanges, according to preliminary data....
SWKS: 62.14 (+1.26), SLXP: 138.55 (-0.95), DIS: 92.00 (+1.00), LOCO: 37.30 (+0.95)

Salix Pharmaceuticals Reports 3Q2014 Results
Business Wire - Thu Nov 06, 3:08PM CST
--3Q14 EBITDA Increases 63% Year-over-Year to $161 million
SLXP: 138.55 (-0.95)

Salix Pharmaceuticals Appoints Acting Chief Financial Officer
Business Wire - Thu Nov 06, 3:01PM CST
Salix Pharmaceuticals, Ltd. (NASDAQ: SLXP) ("Salix" or the "Company" today announced the appointment of Timothy J. Creech as Acting Chief Financial Officer of the Company, effective immediately. He succeeds Adam C. Derbyshire, who resigned his position at the Company.
SLXP: 138.55 (-0.95)

Stocks Cling To Modest Gains; Advance Auto Rebounds
at Investor's Business Daily - Thu Nov 06, 2:04PM CST
Stocks continued to hold slim gains Thursday afternoon. The Dow Jones industrial average led with a 0.3% gain, while the S&P 500 was up 0.2%. But the Nasdaq lagged with a 0.1% gain amid weakness in solar and chips. Volume was tracking lower across...
MNST: 100.48 (+1.31), ANET: 87.25 (+3.13), AAP: 145.56 (-3.81), SLXP: 138.55 (-0.95), DIS: 92.00 (+1.00), CDW: 32.48 (+1.15), NVDA: 20.22 (+0.09), FSLR: 56.41 (+0.15), LNKD: 224.65 (+6.47), LGF: 32.06 (+0.04), LOCO: 37.30 (+0.95), KING: 13.19 (-0.41)

Stocks Down As Early Gains Fade; Generac Dives, Tableau Soars
at Investor's Business Daily - Thu Nov 06, 9:41AM CST
Stocks twisted opening gains into thin losses Thursday, as economic news and company reports fed the bulk of early action. The S&P 500 dipped 0.2%. The Nasdaq hovered a fraction into the red and the Dow Jones industrial average held effectively flat....
WFM: 44.85 (+4.86), TSLA: 241.22 (+10.25), AAP: 145.56 (-3.81), AKRX: 37.88 (-3.80), SLXP: 138.55 (-0.95), DIS: 92.00 (+1.00), GNW: 8.66 (-5.41), CDW: 32.48 (+1.15), NVDA: 20.22 (+0.09), QCOM: 70.58 (-6.62), GNRC: 42.09 (-1.43), LOCO: 37.30 (+0.95), DATA: 84.29 (+7.79)

Video: 3 IBD 50 Tech, Drug Stocks With Earnings Thursday
at Investor's Business Daily - Wed Nov 05, 7:01PM CST
Several IBD 50 drug and tech companies release quarterly earnings results on Thursday: Akorn, Salix Pharmaceuticals and Skyworks Solutions. All three have IBD's highest possible Composite Rating, a 99, meaning their shares outperform 99% of all...
AGN: 197.40 (+1.08), ACT: 250.38 (+2.47), SWKS: 62.14 (+1.26), AKRX: 37.88 (-3.80), SLXP: 138.55 (-0.95), AAPL: 108.70 (-0.16)

Salix, Skyworks Lead 6 IBD50 EarningsReports On Tap
at Investor's Business Daily - Tue Nov 04, 7:02AM CST
Earnings season continues to barrel forward, and investors are anticipating results from several top drugmakers this upcoming week. This week's IBD 50, a roundup of top-rated growth stocks with solid fundamentals, boasts six companies reporting...
DRTX: 24.10 (+0.10), AGN: 197.40 (+1.08), ACT: 250.38 (+2.47), SWKS: 62.14 (+1.26), AKRX: 37.88 (-3.80), JAZZ: 172.37 (+5.19), SLXP: 138.55 (-0.95), AAPL: 108.70 (-0.16), ATHM: 45.23 (+1.15)

Pharming and Salix partnership unveils RUCONEST for treating acute angioedema attacks in patients with HAE in the US
M2 - Mon Nov 03, 3:45AM CST
Pharming Group NV (Amsterdam HARM.AS) and Salix Pharmaceuticals (NasdaqGS:SLXP) on Monday jointly announced the introduction of RUCONEST (C1 Esterase Inhibitor [Recombinant]) 50 IU/kg in the US for the treatment of acute angioedema attacks in adult and adolescent patients with hereditary angioedema (HAE).
SLXP: 138.55 (-0.95)

Salix and Pharming Announce the Launch of RUCONEST(R) in the U.S. for the Treatment of Acute Angioedema Attacks in Patients with Hereditary Angioedema (HAE)
Business Wire - Mon Nov 03, 12:00AM CST
Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP) and Pharming Group NV (EURONEXT: PHARM) today announced the launch of RUCONEST(R) (C1 Esterase Inhibitor [Recombinant]) 50 IU/kg in the United States for the treatment of acute angioedema attacks in adult and adolescent patients with hereditary angioedema (HAE). Effectiveness in clinical studies was not established in HAE patients with laryngeal attacks. Today's announcement follows the July approval of the drug by the Food and Drug Administration.
SLXP: 138.55 (-0.95)

SmarTrend Watching for Potential Pullback in Shares of Salix Pharmaceuticals After 3.69% Gain
Comtex SmarTrend(R) - Thu Oct 30, 4:19PM CDT
Salix Pharmaceuticals (NASDAQ:SLXP) traded in a range yesterday that spanned from a low of $138.87 to a high of $145.10. Yesterday, the shares gained 3.7%, which took the trading range above the 3-day high of $141.76 on volume of 1.2 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
SLXP: 138.55 (-0.95)

Fitch: M&A Premiums Fall on Inversion Crackdown
Business Wire - Mon Oct 27, 8:10AM CDT
Tax inversion deals have effectively been repriced by the US Treasury signaling an end to "hop-scotch" loans and other tax structuring opportunities, according to Fitch Ratings. AbbVie's purchase of Shire and the planned merger of Salix Pharmaceuticals and Cosmo Technologies, both pulled since the Treasury announcement, were scuttled by the changed economics. However, Fitch expects companies with global growth ambitions will continue to seek foreign acquisitions to optimize their long-term tax affairs.
SLXP: 138.55 (-0.95)

Stocks Hold Near Session Highs; Drugmakers Shine Again
at Investor's Business Daily - Fri Oct 24, 1:50PM CDT
Stocks looked poised to end the week on a positive note Friday. The Dow Jones industrial average added 0.6%; the S&P 500 rose 0.5% and the Nasdaq picked up 0.4%. NYSE was tracking lower than Thursday's level. Nasdaq volume was tracking close to...
AMZN: 296.64 (+0.12), SYNA: 63.54 (-2.31), EW: 123.57 (+2.47), SLXP: 138.55 (-0.95), MTX: 75.61 (+0.15), CELG: 107.14 (+1.99), GILD: 106.94 (+0.89), JAZZ: 172.37 (+5.19), ALXN: 193.14 (+3.25), PG: 88.90 (-0.10), CTCT: 34.58 (+0.08)

Shares of SLXP Down 10.6% Since Downtrend Call on Shares
Comtex SmarTrend(R) - Fri Oct 24, 9:33AM CDT
SmarTrend identified a Downtrend for Salix Pharmaceuticals (NASDAQ:SLXP) on October 2nd, 2014 at $152.63. In approximately 3 weeks, Salix Pharmaceuticals has returned 10.61% as of today's recent price of $136.44.
SLXP: 138.55 (-0.95)

Salix Pharmaceuticals Announces 3Q2014 Financial Results Conference Call and Webcast
Business Wire - Thu Oct 23, 6:00AM CDT
Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP) today announced that the Company will report third quarter 2014 financial results following the close of the U.S. financial markets on Thursday, November 6, 2014.
SLXP: 138.55 (-0.95)